(2R)-2,4-dimethylpentanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2R)-2,4-dimethylpentanamide
• 化学式: C₇H₁₅NO
• 分子量: 129.2
• InChiKey: POLRBXCXVRASTG-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180148457A1

  公开（公告）日：2018-05-31

  The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 and R 10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是CaM激酶抑制剂，用于治疗各种疾病状态，包括心房颤动和心肌梗死。在特定实施例中，化合物的一般结构由公式I给出：其中R1、R2、R3、R4、R5、R6、R9和R10如本文所述，涉及化合物的制备和使用方法以及含有相同化合物的药物组合物。
• TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20180065983A1

  公开（公告）日：2018-03-08

  Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

  本文描述了具有磷脂酰肌醇-3激酶（PI3K）调节活性或功能的三环化合物，具有以下结构的Formula I结构：或其立体异构体、互变异构体或药学上可接受的盐，以及所述的取代基和结构特征。还描述了包括Formula I化合物的药物组合物和药物，以及使用这种PI3K调节剂的方法，单独或与其他治疗剂联合治疗依赖于PI3K失调的疾病或病况。
• 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20140243336A1

  公开（公告）日：2014-08-28

  The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了某些含有2-吡啶基羧酰胺的化合物，其化学式为(I)，或其药学上可接受的盐，其中A和B如本文所定义。本发明还提供了包括这些化合物的药物组合物，并且提供了使用这些化合物治疗由脾脏酪氨酸激酶（Syk）介导的疾病或症状的方法。
• BICYCLIC OXA-LACTAM KINASE INHIBITORS
  申请人：PORTOLA PHARMACEUTICALS, INC.

  公开号：US20150252056A1

  公开（公告）日：2015-09-10

  Provided are bicyclic oxa-lactam compounds for inhibition of JAK/Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.

  提供了双环氧内酰胺化合物，用于抑制JAK/Syk激酶，用于制备这种化合物的中间体，其制备方法，制备这种化合物的制药组合物，抑制JAK/Syk激酶活性的方法，以及治疗至少部分由JAK/Syk激酶活性介导的疾病的方法。
• US9216173B2
  申请人：——

  公开号：US9216173B2

  公开（公告）日：2015-12-22